A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia

J Neurosci. 2006 Mar 15;26(11):2914-22. doi: 10.1523/JNEUROSCI.5326-05.2006.

Abstract

Abnormal function of NMDA receptor has been suggested to be correlated with the pathogenesis of Parkinson's disease (PD) as well as with the development of l-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Here we show that NMDA receptor NR2 subunits display specific alterations of their subcellular distribution in striata from unilateral 6-hydroxydopamine-lesioned, L-DOPA-treated dyskinetic, and L-DOPA-treated nondyskinetic rats. Dyskinetic animals have significantly higher levels of NR2A subunit in the postsynaptic compartment than all other experimental groups, whereas NR2B subunit shows a significant reduction in both dopamine-denervated and dyskinetic rats. These events are paralleled by profound modifications of NMDA receptor NR2B subunit association with interacting elements, i.e., members of the membrane-associated guanylate kinase (MAGUK) protein family postsynaptic density-95, synapse-associated protein-97 and synapse-associated protein-102. Treatment of nondyskinetic animals with a synthetic peptide (TAT2B) able to affect NR2B binding to MAGUK proteins as well as synaptic localization of this subunit in nondyskinetic rats was sufficient to induce a shift of treated rats toward a dyskinetic motor behavior. These data indicate abnormal NR2B redistribution between synaptic and extrasynaptic membranes as an important molecular disturbance of the glutamatergic synapse involved in L-DOPA-induced dyskinesia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / chemistry
  • Adaptor Proteins, Signal Transducing / metabolism*
  • Animals
  • Antiparkinson Agents / therapeutic use*
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Calcium-Calmodulin-Dependent Protein Kinases / metabolism
  • Corpus Striatum / chemistry
  • Corpus Striatum / ultrastructure
  • Disks Large Homolog 4 Protein
  • Intracellular Signaling Peptides and Proteins / chemistry
  • Intracellular Signaling Peptides and Proteins / metabolism*
  • Levodopa / therapeutic use*
  • Male
  • Membrane Proteins / chemistry
  • Membrane Proteins / metabolism*
  • Motor Activity / drug effects
  • Neuropeptides / chemistry
  • Neuropeptides / metabolism*
  • Oxidopamine / toxicity
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / drug therapy
  • Parkinsonian Disorders / metabolism*
  • Parkinsonian Disorders / pathology
  • Phosphorylation
  • Protein Binding
  • Protein Interaction Mapping
  • Protein Processing, Post-Translational
  • Protein Structure, Tertiary
  • Protein Transport
  • Protein-Tyrosine Kinases / metabolism
  • Psychomotor Performance / drug effects
  • Rats
  • Rats, Wistar
  • Receptors, N-Methyl-D-Aspartate / analysis*
  • Receptors, N-Methyl-D-Aspartate / chemistry
  • Receptors, N-Methyl-D-Aspartate / metabolism*
  • Recombinant Fusion Proteins / pharmacology*
  • Recombinant Fusion Proteins / therapeutic use*
  • Subcellular Fractions / chemistry
  • Synapses / chemistry

Substances

  • Adaptor Proteins, Signal Transducing
  • Antiparkinson Agents
  • Disks Large Homolog 4 Protein
  • Dlg1 protein, rat
  • Dlg3 protein, rat
  • Dlg4 protein, rat
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • NR2A NMDA receptor
  • NR2B NMDA receptor
  • Neuropeptides
  • Receptors, N-Methyl-D-Aspartate
  • Recombinant Fusion Proteins
  • TAT2B protein
  • Levodopa
  • Oxidopamine
  • Protein-Tyrosine Kinases
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Calcium-Calmodulin-Dependent Protein Kinases